Inclusion Criteria

Inclusion Criteria

- Males and females of at least 18 years of age with metastatic RCC of predominantly
clear cell histology who have received 0 to 2 prior treatment regimens for metastatic
disease.

- Measurable disease according to Response Criteria for Solid Tumors.

- Negative pregnancy test (women of childbearing potential only).

- Pretreatment laboratory levels that meet specific criteria.

- Signed and dated informed consent and authorization to use protected health
information (in accordance with national and local patient privacy regulations

- Patients must have failed at least one approved or investigational tyrosine kinase
inhibitor (TKI).

Exclusion Criteria

- Any of the following histologies of RCC: papillary, chromophobe, collecting duct, or
unclassified.

- Known sensitivity to murine proteins or chimeric antibodies or other components of
the product.

- Use of any investigational drug within 4 weeks prior to screening or 5 half-lives of
the prior investigational drug (whichever is longer).

- Systemic chemotherapy, immunotherapy, radiation therapy, or monoclonal antibody
therapy within 4 weeks of M200 administration.

- Documented central nervous system (CNS) tumor or CNS metastasis.

- History of thromboembolic events and bleeding disorders within the past year.

- Medical conditions that may be exacerbated by bleeding.